Related Experiment Videos
[Beta-amyloid protein: recent progress in basic research and therapeutic approaches].
1Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo.
Rinsho Shinkeigaku = Clinical Neurology
|September 19, 2002
Summary
Amyloid beta 42 (A beta 42) deposition is an early Alzheimer's disease (AD) hallmark. Targeting A beta production via secretase inhibitors or vaccines offers new therapeutic avenues for AD.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Context:
- Alzheimer's disease (AD) is characterized by amyloid beta (A beta) protein deposition in the brain.
- A beta peptides are derived from the beta amyloid precursor protein (beta APP).
Purpose:
- To investigate the role of A beta 42 in early Alzheimer's disease pathology.
- To explore the therapeutic potential of targeting A beta production pathways.
Summary:
- The deposition of A beta 42 is identified as an early pathological event in AD.
- Mutations in beta APP, presenilin 1 (PS1), and presenilin 2 (PS2) genes are linked to increased A beta 42 production.
- PS1 and PS2 function as gamma-secretase, cleaving beta APP and Notch.
- The beta-amyloid hypothesis is supported by therapeutic strategies like A beta vaccines and secretase inhibitors.
Impact:
- This research validates the beta-amyloid hypothesis in AD pathogenesis.
- Findings support the development of novel AD therapies targeting A beta production and accumulation.